> For the complete documentation index, see [llms.txt](https://docs.owkin.com/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://docs.owkin.com/explore-and-analyse-data/data-catalog/browse-for-additional-datasets-of-interests/mosaic-window.md).
# Mosaic Window
{% hint style="info" %}
**Availability**
The use of this dataset is free but requires to users to be habilitated through a research objective that is reviewed by the producing consortium. This dataset can be made available for a trial on K Pro tool at your request.
{% endhint %}
MOSAIC Window is a curated subset of the groundbreaking MOSAIC dataset, available through K Pro. It includes spatial omics and multimodal data from **100 patients** across 8 cancer types:
* **BLCA (Bladder Cancer):** 15 patients
* **OV (Ovarian Cancer):** 15 patients
* **GBM (Glioblastoma):** 10 patients
* **DLBCL (Diffuse Large B-cell Lymphoma):** 10 patients
* **MESO (Mesothelioma):** 10 patients
* **NSCLC (Non-Small Cell Lung Cancer):** 15 patients
* **HNSCC (Head & Neck Squamous Cell Carcinomas):** 10 patients
* **BRCA (Breast Cancer):** 15 patients
This unique resource enables researchers to explore tumor biology at near single-cell resolution, providing detailed insight into tumor and immune cell interactions.
**MOSAIC Window Patient Details**
**BLCA (15 patients):**
* Stage II and III urothelial carcinoma (one squamous cell carcinoma)
* Derived from upfront cystectomies
* Most patients receiving complete lymph node dissection
* Some treated with adjuvant chemotherapy, chemotherapy, or immune checkpoint inhibitors (ICI) at relapse, with or without radiotherapy
**OV (15 patients):**
* FIGO stage II to IV high grade serous carcinoma
* 7 baseline, 2 post-NACT, 6 relapse lesions
* Treated by upfront or post-NACT interval debulking surgeries and chemotherapy
* Additional treatments: Bevacizumab, PARP inhibitors, and ICI in first or later lines
**GBM (10 patients):**
* Glioblastoma as per WHO 2021 definition, all IDH wildtype
* 6 unmethylated and 4 methylated MGMT promoter samples
* Obtained from baseline surgery before standard adjuvant therapy
* 1 to 3 brain tumor sites, tumor sizes 27 to 80mm diameter
* 5 patients received Bevacizumab at relapse
**DLBCL (10 patients):**
* Ann Arbor stage III or IV
* 3 Activated B-cell-like type (ABC), 6 Germinal center B-cell group (GCB), 1 unknown subtype
* Obtained at baseline before R-CHOP therapy
* Targeted interventions at relapse
**MESO (10 patients):**
* Stage I to III pleural mesotheliomas
* 5 epithelioid, 5 biphasic
* 9 baseline biopsies/surgeries, 1 post-NACT sample
* 4 patients treated by NACT (1 partial response, 3 progressive diseases)
* 4 patients received anti-PD-1 ICI at relapse (monotherapy or combination with anti-CTLA4)
**NSCLC (15 patients):**
* 10 Adenocarcinoma and 5 squamous cell carcinoma
* Male-predominant (10/15)
* 8 patients ≥ 70 years old
* Mostly early-to-intermediate stage at diagnosis (Stage I: 5, Stage II: 4, Stage III: 2, Stage IV: 1)
* 50% former smokers, 29% active smokers and 21% never smokers 21.4%
* 14 patients received surgical resection
* 4 patients with KEAP1 mutations, 2 patients with TP53 mutations and 1 patient with a co-mutation of KEAP1+STK11
* 9 patients had upfront surgery, 3 patients had neoadjuvant chemotherapy (NACT) before surgery and 1 patient had initial 1L immunotherapy combination with chemotherapy for a metastatic disease.
* 11 samples are from baseline surgery, 3 from post-NACT surgical samples and 1 baseline sample for the patient treated with upfront chemotherapy + immunotherapy
**HNSCC (10 patients):**
* 6 male patients , mostly between 50 and 69 years old
* Majority of patients were advanced-stage at diagnosis — Stage IV (5), Stage III (2)
* All the patients received immunotherapy in the Recurrent Unresectable and/or Metastatic (R/M) setting.
* 9/10 patients had surgical resection.
* 4 active smokers, 5 former smokers, 1 never-smoker
* 3 patients had CPS > 20
* 1 patient has positive HPV status by p16 IHC
* 6 patients had upfront surgery with various adjuvant strategies and 2 patients had initial 1L anti-PD1 treatment
* 6 patients have paired samples from primary tumour and recurrence, including 1 patient with an additional post-Immunotherapy progression sample
**BRCA (15 patients):**
* 10 patients had infiltrating ductal adenocarcinoma
* 10 patients had triple-negative breast cancer (TNBC)
* Mostly early/intermediate stage disease at diagnosis— Stage I (3), II (7), III (2)
* 8 patients were postmenopausal and 7 were premenopausal
* All patients are BRCA1 / BRCA2 wild-type, and 2 patients had PIK3CA mutations
* 9 patients were treated with neoadjuvant chemotherapy (NACT) before surgery
* 2 patients have paired samples at baseline and post-NACT surgery, including 1 patient with an additional sample at disease recurrence.
* 4 other patients have paired samples at post-NACT surgery and disease recurrence.
* 1 samples is from a baseline metastatic site
---
# Agent Instructions
This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com.
## Querying This Documentation
If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.
Perform an HTTP GET request on the current page URL with the `ask` query parameter, and the optional `goal` query parameter:
```
GET https://docs.owkin.com/explore-and-analyse-data/data-catalog/browse-for-additional-datasets-of-interests/mosaic-window.md?ask=&goal=
```
`ask` is the immediate question: it should be specific, self-contained, and written in natural language.
`goal` is optional and describes the broader end goal you are ultimately trying to accomplish on behalf of the user. GitBook uses it to tailor the answer towards what is most useful for that goal.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.
Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.